Your shopping cart is empty.

ONCOPULMONpgx

Farmacogenética del tratamiento del cáncer de pulmón
Pharmacogenetics of lung cancer treatment
Pharmacogenetics explains how genes affect a person's response to certain medications. Each person is genetically different and requires personalised medication.
Precio: 
425 €

Sample type:

Saliva

Delivery period:

30 - 40 days from sample receipt.
Last update of the document Apr, 05/04/2022 - 14:18

The ONCOPULMONpgx profile is indicated for patients who will be treated with oncology drugs for lung cancer, or patients who are already on treatment. It includes the most widely used drugs approved by the US National Cancer Institute.

The profile includes 43 drugs, including, among others, cisplatino, paclitaxel and gemcitabina, as well as the cannabinoid compounds CBD and THC (cannabidiol and tetrahydrocannabinol) used for the treatment of pain.

The objective is a personalized therapy based on genetics, with the aim of obtaining greater efficacy and fewer adverse effects or therapeutic failures.

Genetic variants related mainly to the elimination of these drugs are analysed. In the case of lower elimination, adverse effects may occur due to toxicities; if elimination is higher, it may lead to therapeutic failure.

By performing this profile, it is possible to know whether the treatment will produce the expected effect, whether it is preferable to modify the dose, or to replace the drug with alternatives.

Occasionally, patients treated with paclitaxel may be found to have elevated plasma concentrationsincreasing the risk of toxicity.This is mainly due to the presence of a polymorphism in one of the genes involved in the elimination of paclitaxel.

 

Interpretation of the polytherapy report 

 
In addition to knowing the genetics, which is essential for the efficacy of the treatment, it is essential to know the interactions caused by the combined use of medication, nutritional supplements and the patient's lifestyle.
 
One example is the co-administration of crizotinib with grapefruit juice, which reduces the elimination of crizotinib and consequently increases the risk of adverse effects.
 
All these possible interactions are taken into account in the g-Nomic® Pharmacogenetics interpretation software, thus completing the correct prescription of drugs.
 
 

You will receive the sample collection kit. You can request additional kits if you need it.

Sample collection kit content:
You will get a box with sample collection kit. Within the kit you will find:

  1. Saliva collector.
  2. Instructions for the sample collection.
  3. Informed consent sheet and application form.
  4. Security bag to enter the sample for shipment.
  5. Envelope bag.

Process to follow:

  1. Follow the instructions for collecting the sample.
  2. After obtaining the sample, include it in the return envelope, remember to put into the informed consent sheet and the application form.
  3. No shipping costs on Spanish territory.
  4. An email confirmation will be sent when your sample si received.
  5. When the study will be completed you will receive a new e-mail to inform you that your report is already available in "My results".

Info producto mobile

Profile Information

The ONCOPULMONpgx profile is indicated for patients who will be treated with oncology drugs for lung cancer, or patients who are already on treatment. It includes the most widely used drugs approved by the US National Cancer Institute.

The profile includes 43 drugs, including, among others, cisplatino, paclitaxel and gemcitabina, as well as the cannabinoid compounds CBD and THC (cannabidiol and tetrahydrocannabinol) used for the treatment of pain.

The objective is a personalized therapy based on genetics, with the aim of obtaining greater efficacy and fewer adverse effects or therapeutic failures.

Genetic variants related mainly to the elimination of these drugs are analysed. In the case of lower elimination, adverse effects may occur due to toxicities; if elimination is higher, it may lead to therapeutic failure.

By performing this profile, it is possible to know whether the treatment will produce the expected effect, whether it is preferable to modify the dose, or to replace the drug with alternatives.

Occasionally, patients treated with paclitaxel may be found to have elevated plasma concentrationsincreasing the risk of toxicity.This is mainly due to the presence of a polymorphism in one of the genes involved in the elimination of paclitaxel.

 

Interpretation of the polytherapy report 

 
In addition to knowing the genetics, which is essential for the efficacy of the treatment, it is essential to know the interactions caused by the combined use of medication, nutritional supplements and the patient's lifestyle.
 
One example is the co-administration of crizotinib with grapefruit juice, which reduces the elimination of crizotinib and consequently increases the risk of adverse effects.
 
All these possible interactions are taken into account in the g-Nomic® Pharmacogenetics interpretation software, thus completing the correct prescription of drugs.
 
 

Sample type and process to follow

You will receive the sample collection kit. You can request additional kits if you need it.

Sample collection kit content:
You will get a box with sample collection kit. Within the kit you will find:

  1. Saliva collector.
  2. Instructions for the sample collection.
  3. Informed consent sheet and application form.
  4. Security bag to enter the sample for shipment.
  5. Envelope bag.

Process to follow:

  1. Follow the instructions for collecting the sample.
  2. After obtaining the sample, include it in the return envelope, remember to put into the informed consent sheet and the application form.
  3. No shipping costs on Spanish territory.
  4. An email confirmation will be sent when your sample si received.
  5. When the study will be completed you will receive a new e-mail to inform you that your report is already available in "My results".

Documentación